Results for tag: "Synribo"

Synribo is a drug used to treat chronic myelogenous leukemia (CML). It is a tyrosine kinase inhibitor (TKI) that works by blocking the activity of the BCR-ABL protein, which is responsible for the uncontrolled growth of cancer cells in CML. Synribo is approved by the US Food and Drug Administration (FDA) for the treatment of CML in adults who have failed or are intolerant to prior therapy. It is also approved for use in combination with other drugs for the treatment of CML in adults who are newly diagnosed. Synribo is marketed by Teva Pharmaceuticals, a global pharmaceutical company based in Israel. Other companies in the market include Novartis, Pfizer, and Bristol-Myers Squibb. These companies are involved in the development, manufacture, and marketing of Synribo and other drugs used to treat CML. Show Less Read more